Do you know the benefits, risks and feasibility of providing intensive glycemic control based on Gliclazide MR?
Thanks to the ADVANCE Trial, we now know that an intensive glucose control - based on incremental titration of Gliclazide MR and other therapies - is able to reduce HbA1c levels to 6.5% effectively and consistently through time in patients with type 2 diabetes, thus achieving long-term protection. This approach significantly reduced the risk of microvascular events (non-fatal MI, non-fatal stroke and cardiovascular death) and microvascular events (retinopathy and nephropathy) by 10%, in addition to demonstrating a very good safety profile with a low hypoglycemia risk and without any other side effects.
To know more : Click here
"It can also interest you"
March 17, 2022
How does the inclusion of new therapies impact glycemic control?
December 13, 2021
Zaccardi Study: Comparative effectiveness of Gliclazide MR vs. Sitagliptin as s…
December 1, 2021
PAMPA model of gliclazide permeability: The impact of probiotic bacteria and bi…
Keep up to date with our content
Subscribe to our newsletter so that you are always up to date with the news.
You can unsubscribe at any time by clicking on the link in our emails.